Foundation Medicine (NASDAQ:FMI)

CAPS Rating: 3 out of 5

FMI News and Commentary

Caps

How do you think FMI will perform against the market?

Add Stock to CAPS Watchlist

All Players

46 Outperform
3 Underperform
 

All-Star Players

13 Outperform
2 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top FMI Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

TMFInnovator (58.99)
Submitted September 03, 2014

Foundation Medicine runs high-speed genomic tests to profile individual patients, identify genetic abnormalities, and then recommend the best course of action for their treatment. I expect them to benefit from continued adoption of personalized… More

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

FMI VS S&P 500 (SPY)

Fools bullish on FMI are also bullish on:

Recent Community Commentary

Read the most recent pitches from players about FMI.

Recs

0
Member Avatar TMFEBCapital (42.88) Submitted: 10/10/2017 3:52:29 PM : Outperform Start Price: $44.05 FMI Score: -7.73

This company's on the cutting edge of genetic screening for cancer mutations and a potential FDA approval for its Foundation One platform by year's end -- and the corresponding issuance of a distinct Medicare code at the same time -- could significantly accelerate the adoption of screening. Personalized medicine is where cancer treatment is heading, and currently, only 150k of an addressable 1 mn person market in advanced cancer is being screened. Over time, expansion of this market could make the addressable market in the U.S. 2 million. Given Roche already own 50% plus of this one, there's plenty of financial backing to make this a reality.

Recs

0
Member Avatar adamicius (< 20) Submitted: 4/2/2017 10:56:45 AM : Outperform Start Price: $32.45 FMI Score: +17.62

company involved in a promising new field of science - genomic diagnostics for dangerous diseases. The company has promising partnerships (eg with Roche) but it has yet to prove long term viability. Highly speculative

Recs

0
Member Avatar Astokian (< 20) Submitted: 6/16/2014 12:30:56 PM : Outperform Start Price: $22.70 FMI Score: +48.62

The technology will find a use with a growing base of users

Leaderboard

Find the members with the highest scoring picks in FMI.

Score Leader

Signature007

Signature007 (39.78) Score: +212.18

An IPO dog.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
flounderuiuc 70.09 12/7/2015 Outperform 5Y $16.81 +144.50% +22.88% +121.61 0 Comment
majorguelth 63.65 1/14/2016 Outperform NS $16.19 +153.86% +35.64% +118.22 0 Comment
coleman205 32.04 11/9/2015 Outperform 5Y $17.48 +135.13% +22.85% +112.28 0 Comment
stereotyp72 63.46 1/24/2017 Outperform 5Y $18.60 +120.97% +13.56% +107.40 0 Comment
SnoopyOne 62.55 3/14/2016 Outperform 5Y $18.24 +125.33% +26.82% +98.51 0 Comment
afurst < 20 10/9/2014 Outperform 1Y $19.18 +114.29% +30.96% +83.33 0 Comment
pmadiraju < 20 9/23/2014 Outperform 5Y $20.00 +105.50% +29.57% +75.93 0 Comment
BRANTE 45.47 10/13/2014 Outperform 5Y $19.56 +110.12% +34.99% +75.13 0 Comment
YMY 48.73 9/22/2014 Outperform 5Y $20.77 +97.88% +28.33% +69.55 0 Comment
misunderestimate < 20 5/19/2014 Outperform 5Y $20.37 +101.77% +36.99% +64.78 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for FMI.

Featured Broker Partners